Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (NASDAQ: ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Nuvectis is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...

SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...